Manganese-Enhanced T1 Mapping in the Myocardium of Normal and Infarcted Hearts
Table 2
Mean LVEF and mean difference in LVEF versus baseline for the cohort of healthy rats administered MnCl2, EVP1001-1, and mangafodipir.
Time point (minutes)
Mean LVEF (%) and mean difference in LVEF (%)
Baseline
15
30
50
MnCl2 + saline
67.5 ± 5.6
73.4 ± 6.3
72.4 ± 5.6
71.1 ± 2.0
Mean difference (vs. baseline)
—
5.8 ± 1.3
4.9 ± 2.6
3.6 ± 5.1
MnCl2 + diltiazem
65.0 ± 8.0
58.2 ± 3.9
58.3 ± 6.8
60.1 ± 12.5
Mean difference (vs. baseline)
—
−3.2 ± 0.6
−3.1 ± 2.6
−4.8 ± 5.1
EVP1001-1 + saline
65.3 ± 0.7
71.0 ± 5.5
67.1 ± 2.5
67.1 ± 3.8
Mean difference (vs. baseline)
—
4.0 ± 6.8
−0.3 ± 2.6
0.7 ± 5.5
EVP1001-1 + diltiazem
69.6 ± 6.4
68.3 ± 8.4
63.4 ± 7.3
65.6 ± 7.8
Mean difference (vs. baseline)
—
−0.5 ± 3.7
−4.1 ± 4.0
−4.1 ± 3.7
Mangafodipir 22 μmol/kg
63.2 ± 6.3
66.9 ()
65.8 ± 8.2
67.1 ± 7.4
Mean difference (vs. baseline)
—
6.9 ()
4.7 ± 7.1
2.5 ± 4.5
Mangafodipir 44 μmol/kg + Saline
73.5 ± 3.1
76.8 ()
76.1 ± 4.9
77.0 ± 4.1
Mean difference (vs. baseline)
—
3.9 ()
4.5 ± 1.1
4.6 ± 3.6
Mangafodipir 44 μmol/kg + diltiazem
64.1 ± 4.8
64.0 ± 8.1
62.5 ± 7.3
62.0 ± 9.5
Mean difference (vs. baseline)
—
0.81 ± 6.53
−0.2 ± 6.9
−1.0 ± 4.7
Group sizes for EVP1001-1 and mangafodipir 22 μmol/kg and for MnCl2 and mangafodipir 44 μmol/kg. Calculation of mean only from those time points with measurements available. Post hoc Bonferroni multiple comparisons significance at each time point as compared to saline control indicated by asterisk.
